Yale Jen
Stock Analyst at Laidlaw
(0.24)
# 4,527
Out of 4,693 analysts
76
Total ratings
26.7%
Success rate
-8.7%
Average return
Main Sectors:
Stocks Rated by Yale Jen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EYPT EyePoint | Maintained: Buy | $50 → $48 | $4.58 | +948.03% | 4 | Aug 17, 2026 | |
| NCEL NewcelX | Initiated Coverage: Buy | $23 | $3.29 | +599.09% | 2 | Jul 13, 2026 | |
| KZIA Kazia Therapeutics | Initiated Coverage: Buy | $25 | $12.63 | +97.94% | 1 | Apr 15, 2026 | |
| FEMY Femasys | Initiated Coverage: Buy | $130 | $3.26 | +3,887.73% | 1 | Nov 20, 2025 | |
| NSRX Nasus Pharma | Initiated Coverage: Buy | $22 | $3.83 | +475.16% | 1 | Sep 29, 2025 | |
| VKTX Viking Therapeutics | Reiterated: Buy | $110 | $33.67 | n/a | 3 | Aug 20, 2025 | |
| SNTI Senti Biosciences Holdings | Initiated Coverage: Buy | $5 | $0.34 | n/a | 1 | Jun 6, 2025 | |
| ALDX Aldeyra Therapeutics | Reiterated: Buy | $11 | $1.49 | n/a | 4 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiated Coverage: Buy | $19 | $23.06 | n/a | 1 | Mar 17, 2025 | |
| LFWD Lifeward | Initiated Coverage: Buy | $10 | $7.20 | n/a | 1 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 → $100 | $3.66 | n/a | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $68 | $59.88 | n/a | 8 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 → $20 | $1.42 | n/a | 5 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $48 | $113.67 | n/a | 1 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.994 | n/a | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $79 | $16.23 | n/a | 6 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7.5 → $225 | $1.09 | n/a | 3 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 → $25 | $0.000001 | n/a | 5 | Jun 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $25 | $0.143 | n/a | 1 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $5.11 | n/a | 2 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0081 | n/a | 2 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $2.44 | n/a | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.66 | n/a | 3 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 → $10 | $0.0131 | n/a | 2 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 → $20 | $0.4765 | n/a | 3 | Mar 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5.75 | $9.33 | n/a | 1 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.59 | n/a | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $8.5 | $1.52 | n/a | 2 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0013 | n/a | 2 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $0.68 | n/a | 1 | May 20, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 → $90 | $2.71 | n/a | 2 | Nov 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $5.35 | n/a | 1 | Sep 27, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $3.5 | $3.83 | n/a | 1 | Sep 16, 2014 |
EyePoint
Aug 17, 2026
Maintained: Buy
Price Target: $50 → $48
Current: $4.58
Upside: +948.03%
NewcelX
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $23
Current: $3.29
Upside: +599.09%
Kazia Therapeutics
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $25
Current: $12.63
Upside: +97.94%
Femasys
Nov 20, 2025
Initiated Coverage: Buy
Price Target: $130
Current: $3.26
Upside: +3,887.73%
Nasus Pharma
Sep 29, 2025
Initiated Coverage: Buy
Price Target: $22
Current: $3.83
Upside: +475.16%
Viking Therapeutics
Aug 20, 2025
Reiterated: Buy
Price Target: $110
Current: $33.67
Upside: n/a
Senti Biosciences Holdings
Jun 6, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $0.34
Upside: n/a
Aldeyra Therapeutics
Apr 4, 2025
Reiterated: Buy
Price Target: $11
Current: $1.49
Upside: n/a
Nuvectis Pharma
Mar 17, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $23.06
Upside: n/a
Lifeward
Feb 10, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $7.20
Upside: n/a
Nov 12, 2024
Maintained: Buy
Price Target: $16 → $100
Current: $3.66
Upside: n/a
Oct 8, 2024
Reiterated: Buy
Price Target: $68
Current: $59.88
Upside: n/a
Sep 27, 2024
Reiterated: Buy
Price Target: $22 → $20
Current: $1.42
Upside: n/a
Jul 29, 2024
Initiated Coverage: Buy
Price Target: $48
Current: $113.67
Upside: n/a
Jul 23, 2024
Downgraded: Hold
Price Target: n/a
Current: $0.994
Upside: n/a
Jul 2, 2024
Reiterated: Buy
Price Target: $79
Current: $16.23
Upside: n/a
Jun 14, 2024
Reiterated: Buy
Price Target: $7.5 → $225
Current: $1.09
Upside: n/a
Jun 12, 2024
Maintained: Buy
Price Target: $11 → $25
Current: $0.000001
Upside: n/a
May 28, 2024
Initiated Coverage: Buy
Price Target: $25
Current: $0.143
Upside: n/a
Dec 22, 2023
Downgraded: Hold
Price Target: n/a
Current: $5.11
Upside: n/a
Dec 12, 2023
Downgraded: Hold
Price Target: n/a
Current: $0.0081
Upside: n/a
Aug 28, 2023
Initiated Coverage: Buy
Price Target: $10
Current: $2.44
Upside: n/a
Aug 15, 2023
Downgraded: Hold
Price Target: n/a
Current: $1.66
Upside: n/a
Aug 7, 2023
Reiterated: Buy
Price Target: $30 → $10
Current: $0.0131
Upside: n/a
Mar 14, 2022
Reiterated: Buy
Price Target: $18 → $20
Current: $0.4765
Upside: n/a
Nov 9, 2020
Reiterated: Buy
Price Target: $5.75
Current: $9.33
Upside: n/a
Aug 24, 2020
Downgraded: Hold
Price Target: n/a
Current: $0.59
Upside: n/a
Jul 31, 2020
Maintained: Buy
Price Target: $6 → $8.5
Current: $1.52
Upside: n/a
Aug 9, 2019
Downgraded: Hold
Price Target: n/a
Current: $0.0013
Upside: n/a
May 20, 2019
Initiated Coverage: Buy
Price Target: $10
Current: $0.68
Upside: n/a
Nov 15, 2018
Maintained: Buy
Price Target: $4 → $90
Current: $2.71
Upside: n/a
Sep 27, 2016
Maintained: Hold
Price Target: n/a
Current: $5.35
Upside: n/a
Sep 16, 2014
Initiated Coverage: Buy
Price Target: $3.5
Current: $3.83
Upside: n/a